Patient disposition
DLTs
DISEASE PROGRESSION
The data cutoff for this analysis was November 11, 2019.Six patients were enrolled into Part A between November 13, 2017 and February 14, 2018. All patients in Part A received ≥1 dose of durvalumab and tremelimumab; no patients experienced DLTs. In Part A, reasons for discontinuation included disease progression (durvalumab, Ten patients were enrolled into Part B between July 26, 2018 and January 11, 2019. As no DLTs were experienced in Part A, no dose modifications were required in Part B, and all patients received ≥1 standard dose of chemotherapy, durvalumab, and tremelimumab. In Part B, reasons for discontinuation of durvalumab included patient decision (